Optimizing Automated Insulin Delivery Systems for Pregnancy

Automated insulin delivery (AID) systems have revolutionized modern diabetes care outside of pregnancy, but none of the AID systems currently available in the U.S. are approved for use during pregnancy, none have glucose targets low enough to achieve the stricter fasting glucose targets recommended during pregnancy, and none have algorithms that were designed to respond to the amplified oscillations in glycemia that occur in pregnancy or the progressive changes in insulin resistance observed over the course of gestation. Despite these limitations, many women elect to continue using AID off label during pregnancy based on consideration of individual clinical factors and preferences. This article presents some commonly encountered challenges to off-label AID use and CGM interpretation during pregnancy, along with suggested best-practice workarounds to optimize the care of pregnant individuals with diabetes using AID.

Authors

Institutions

Publication Details

Journal
Diabetes Spectrum
Published
2025-11-01
DOI
https://doi.org/10.2337/dsi25-0009
Primary Topic
Gestational Diabetes Research and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimizing Automated Insulin Delivery Systems for Pregnancy

Denice S. Feig, Emily D. Szmuilowicz
Diabetes Spectrum
Gestational Diabetes Research and Management
article

Optimizing Automated Insulin Delivery Systems for Pregnancy

Denice S. Feig, Emily D. Szmuilowicz
article en

Abstract

Automated insulin delivery (AID) systems have revolutionized modern diabetes care outside of pregnancy, but none of the AID systems currently available in the U.S. are approved for use during pregnancy, none have glucose targets low enough to achieve the stricter fasting glucose targets recommended during pregnancy, and none have algorithms that were designed to respond to the amplified oscillations in glycemia that occur in pregnancy or the progressive changes in insulin resistance observed over the course of gestation. Despite these limitations, many women elect to continue using AID off label during pregnancy based on consideration of individual clinical factors and preferences. This article presents some commonly encountered challenges to off-label AID use and CGM interpretation during pregnancy, along with suggested best-practice workarounds to optimize the care of pregnant individuals with diabetes using AID.

Diabetes SpectrumVol. 38(4)
Northwestern University (US), University of Toronto (CA)
Openalex Percentile: Top 57%
Gestational Diabetes Research and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.